<DOC>
	<DOCNO>NCT01716234</DOCNO>
	<brief_summary>The purpose dose-escalation study evaluate pharmacokinetics , safety , tolerability oral posaconazole immunocompromised child neutropenia expect neutropenia .</brief_summary>
	<brief_title>A Study Safety , Tolerance , Pharmacokinetics Oral Posaconazole Immunocompromised Children ( P03579 )</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Documented anticipated neutropenia expect last least 7 day follow clinical situation : acute leukemia ; myelodysplasia ; severe aplastic anemia ; autologous hematopoietic stem cell transplantation ( HSCT ) recipient ; high risk neuroblastoma ; advanced stage nonHodgkin 's lymphoma ; recipient allogeneic HSCT preengraftment ( neutropenia ) period Participants childbearing potential must use medically accept method contraception throughout study least 30 day stop study medication , unless surgically medically sterile agree remain abstinent . Proven invasive fungal infection ( IFI ) study entry Severe nausea and/or vomit screen Received posaconazole within 10 day screen Unable receive study drug mouth via intestinal ( enteral ) tube Females pregnant , intend become pregnant study , breastfeed History anaphylaxis attribute azole class antifungal agent</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>